Achieving Self-directed Integrated Cancer Aftercare (ASICA) in Melanoma — ASICA  

Melanoma Clinical Trial

Official title: Achieving Self-directed Integrated Cancer Aftercare (ASICA) in Melanoma: A Randomized Patient-focused Trial of Delivering the ASICA Intervention as a Means to Earlier Detection of Recurrent and Second Primary Melanoma

Status Completed

Clinical Trial Summary

The ASICA study is looking at how the UK National Health Service (NHS) might use technology in the future to more effectively support people who have been treated for melanoma.

Clinical Trial Description

All patients who have been treated for melanoma are advised to regularly examine their own skin (total-skin-self-examinations; TSSE) but research has found that many people are not shown how to do this effectively. We are investigating whether a digital app we have developed (ASICA) can help people with melanoma to use a hand-held tablet computer to do more regular and effective TSSE, and whether this would lead to earlier detection of recurrent and new primary melanomas. The ASICA app also uses the internet to enable people to electronically communicate the findings of their TSSE to a specialist nurse. All those who consent to take part in the study will be randomly allocated into one of two groups. One group will use the ASICA app in addition to their normal follow-up, the other group will continue to attend their routine melanoma follow-up only. Participants will be recruited from two UK sites - NHS Grampian and Cambridge University Hospitals. ;

Related Conditions & MeSH terms

• Melanoma

• NCT number: NCT03328247
• Study type: Interventional
• Source: University of Aberdeen
• Status: Completed
• Phase: N/A
• Start date: January 12, 2018
• Completion date: March 31, 2020